Same Indication

Candesartan vs Nivolumab

Candesartan vs Nivolumab: Overview

This comparison examines the pharmacological differences between Candesartan and Nivolumab.

Mechanism of Action

Candesartan: Prodrug hydrolyzed to active form; selective angiotensin II type 1 receptor blocker.

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Pharmacokinetics

Half-life: Candesartan — 9 hours; Nivolumab — 27 days.

Chemical Properties

Molecular Formula: Candesartan — C33H34N6O6.

Molecular Weight: Candesartan — 610.6640 g/mol.

Type: Candesartan — Small molecule; Nivolumab — Antibody.